All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
471 matching companies
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
The 2026-10-29 announcement places KT-621 in Phase 2 for AD and asthma and reports Phase 1 healthy-volunteer results for KT-579. Sanofi is advancing KT-485 in Phase 1; Gilead is preparing a KT-200 CDK2 molecular glue IND.
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
FDA approved ICOTYDE for plaque psoriasis on 2026-03-17. Its prescribing information reports human exposure and food effects.
A U.S. commercial benchmark for oral octreotide, with label evidence for enteric capsule composition and a substantial food effect. Its EU authorization has been withdrawn.
AUBE00 is an oral macrocyclic peptide in Phase 1. LUNA18 was discontinued in 2025; the company report confirms oral absorption in humans.
LUPKYNIS is a U.S.-approved oral treatment for lupus nephritis. Its capsule label discloses lipid and surfactant ingredients.
The discovery and collaboration partner for ICOTYDE. Its website also lists PN-881 (oral IL-17A/F) and other early oral programs; the company is recorded separately from J&J.
CID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
The website explicitly focuses on cell-permeable, orally available cyclic peptides using machine learning, automated design, synthesis, and testing. No named clinical candidates were disclosed.
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
nGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
The PDPS-derived oral peptide pipeline includes a myostatin program listed as IND-enabling, plus other oral candidates; it is recorded separately from the radiopharmaceutical peptide pipeline.
HS-20118 / AVR-001 is an oral IL-23R cyclic peptide with disclosed Phase 1 human data. Rights outside Greater China were licensed to Avere.
AVR-001 is Hansoh's HS-20118, with an exclusive license outside Greater China. A 2026 announcement proposed a merger with NextCure; the transaction is not recorded as closed.
HSK47388 is an oral IL-23 inhibitory peptide in Phase 2 for psoriasis. Relative exposure data support its enhancer formulation, while cyclization and absolute oral bioavailability remain unconfirmed.
SAL0167 is an internally developed cyclic peptide program for hyperlipidemia that received NMPA clinical trial authorization in 2026. Authorization is not treated as evidence of actual dosing.
The website lists oral cyclic peptides NGA-101 (IL-4Rα), NGA-102 (TL1A), and NGA-103 (TSLP). Pipeline stage graphics cannot be verified through text extraction alone.
The MO-PION oral macromolecule platform website explicitly lists semaglutide, heparin, and micafungin applications. Micafungin provides a lead for cyclic peptide applications.
The website explicitly identifies an ORALINK oral α4β7 cyclic peptide co-development program with D&D at lead optimization, recorded separately from radiopharmaceutical / conjugate programs.
ORALINK combines ligand conjugation, lipidation, and excipient strategies. The α4β7 cyclic peptide program with QIC is in lead optimization; its GLP-1 human evidence does not transfer to cyclic peptides.
Coverage expands from sourced records; this database does not claim all biopharma companies.
